Search

everythinglearnresearchcommunity

for

Search:↓

EGFR and MEK inhibitors reduce PD-L1 in hair follicles, possibly causing inflammation.

Alopecia areata is a chronic condition causing hair loss, with new treatments targeting the immune system showing promise.

Hair follicle stem cells reduced hair loss and inflammation in mice with a condition similar to human alopecia.

The cause of Frontal fibrosing alopecia, a type of hair loss, is complex, likely involving immune responses and genetics, but is not fully understood.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

The new aptamer TAGX-0003 shows promise as an effective treatment for hair loss disorder alopecia areata.

The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.

Alopecia areata is caused by immune system issues, and JAK inhibitors might help treat it.

Dandruff might be caused by changes in how hair follicles naturally release oils and an immune response to this imbalance.

The role of antibodies in alopecia is unclear, but JAK inhibitors show promise for treatment.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

γδ T cells can prevent and treat alopecia areata, offering a new therapy option.

Regulatory γδ T cells help protect hair follicles from alopecia areata and promote hair regrowth.

γδTregs can protect hair follicles from alopecia areata and may help regrow hair.

Cell-based therapy using specific immune cells may help treat alopecia areata by promoting hair regrowth.

JAK inhibitors are effective for treating moderate-to-severe alopecia areata.

EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.

Researchers successfully isolated and identified key markers of stem cell-enriched human hair follicle bulge cells.

Stem cell therapies show promise for hair regrowth in alopecia areata but need more research for safety and effectiveness.

Autoimmune diseases with high tissue recovery often relapse and remit, while those with low recovery rarely remit.

Alopecia areata and vitiligo share immune system dysfunction but differ in specific immune responses and affected areas.

ILC1-like cells may contribute to hair loss in alopecia areata.

ILC1-like cells may contribute to hair loss in alopecia areata and could be new treatment targets.

Cells from the lower part of hair follicles are a promising, less invasive option for immune system therapies.

GRK2 is essential for healthy hair follicle function, and its absence can lead to hair loss and cysts.

Alopecia areata is caused by immune attacks on hair follicles, affecting hair growth and quality of life.

The model helps understand and improve treatments for alopecia areata by simulating hair growth and immune cell interactions.

Immortalized hair follicle cells could be useful for regenerative medicine and treating inflammation and oxidative stress.

Plucked hair follicles can help diagnose scalp lupus.

Stem cell activity influences autoimmune disease outcomes by affecting immune responses and tissue regeneration.